HomeNON PROFIT

NON PROFIT

Dramatic Drop in Marijuana Use Among U.S. Youth Over a Decade: (2011 to 2021)

Researchers from Florida Atlantic University’s Schmidt College of Medicine conducted a comprehensive study using data from the Youth Risk Behavior Survey between 2011 and 2021, which surveyed 88,183 adolescents in grades nine through 12. Researchers focused on the overall time trends in use of marijuana as well as variations by gender, race/ethnicity, and school grade. These data provide important insights into the changing landscape of marijuana use among American youth.

New Study Shows Durability of Minimally Invasive Procedure to Combat Knee Pain

Published today in the Journal of Vascular and Interventional Radiology during Pain Awareness Month, the study of genicular artery embolization (GAE) followed 40 patients with moderate-to-severe symptomatic knee OA after their GAE treatment and measured pain scores throughout the 24-month study period. The patients were not candidates for total knee replacement.

ACEP to CMS: Require Hospital Plans to Address Boarding in Emergency Departments

ACEP proposes that CMS update its emergency services Condition of Participation (CoP) with a requirement for hospitals to have a plan in place, and to act on it, when the number of patients boarding in the emergency department for hours, days, or longer until a staffed inpatient bed becomes available exceeds a particular threshold.

Vision-based ChatGPT Shows Deficits Interpreting Radiologic Images

The study’s results were published today in Radiology, a journal of the Radiological Society of North America (RSNA).

Cold Weather Exposure Linked to Increased Risk of Heart Attacks

JACC Editor-in-Chief Harlan M. Krumholz, MD, SM, FACC, said the study reveals a crucial link between cold weather exposure and heart attack risk, highlighting a delayed effect that peaks days after the cold spell.

Ryan Reynolds Announces More to Parkinson’s® Campaign

Ryan Reynolds said, “My father experienced hallucinations and delusions. At the time, we didn’t know any of these types of symptoms were part of his Parkinson’s disease. Like a lot of caregivers, my mom mostly tried to carry these burdens alone. I wish I’d known Parkinson’s disease wasn’t limited to only motor symptoms. I think people and families affected by Parkinson’s can be better prepared to manage hallucinations and delusions if they’re talking early and often about this lesser-known aspect of the disease.”

New Paper Underscores Inflammation’s Role in Atherosclerosis

Peter Libby, MD, President, of the International Atherosclerosis Society and Chair of the White Paper Expert Panel said, "Atherosclerosis is a primary cause of cardiovascular disease, the leading cause of death worldwide. This paper underscores the persistent need for a more complete understanding of the role of inflammation in atherosclerosis progression among physicians globally, how to identify such inflammation, and how to mitigate the inflammation-associated risk of adverse cardiovascular events. These steps are of the utmost importance for the development of effective treatment strategies that can reduce the morbidity and mortality caused by atherosclerotic cardiovascular disease."

Study: Private Equity Acquisitions in Cardiology on the Rise

“Policymakers and clinicians have raised concern about the growing presence of private equity in other medical specialties. Although cardiology is an attractive target for private equity firms, little is known about the number and types of practices that are being acquired,” said Senior Author Rishi K. Wadhera, MD, MPP, MPhil, a cardiologist at Beth Israel Deaconess Medical Center and associate professor at Harvard Medical School in Boston. “Private equity acquisitions in other specialties have been shown to decrease quality and increase costs, so it is critical to understand the impact on cardiology.”

CMT Research Foundation Invests in ReviR Therapeutics Research to Pioneer Small Molecule Therapeutics for CMT1A

"Collaborating with ReviR Therapeutics aligns perfectly with CMTRF's mission to accelerate the development of therapies that can halt or even reverse the progression of CMT," says Cleary Simpson, CEO of the CMT Research Foundation. "Their cutting-edge technology has the potential to transform the lives of those living with this chronic condition by providing a non-invasive, potent, and easily administrable treatment option."